Medicine guide
Teysuno
·
- Prescription status not stated
- Cancer treatments and immune-system medicines
- Active substance
- Tegafur;gimeracil;oteracil
- Made by
- Nordic Group B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Teysuno is indicated in adults: - for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5.1). - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Nordic Group B.V. |
|---|---|
| Active substance | Tegafur;gimeracil;oteracil |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L01BC53 · Cancer treatments and immune-system medicines |
| Authorised on | 2011-03-14 |
| Last updated by the regulator | 2025-10-30 |
| EMA product number | EMEA/H/C/001242 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).